Polish insulin manufacturers face discrimination – Pharmaceutical Industry Association

People who are over the age of 75 in Poland and using insulin are not being refunded, in spite of the fact that they are being refunded for other drugs they require, Piotr Blaszczyk of the Polish Association of Pharmaceutical Industry Employers told the Polish press on Monday. The organization claims that, as a result, producers of the drug, used by 200,000 elderly Poles, face unfair competition, in that it could lead to more purchases of insulin that is produced outside of the country. Some forms of insulin – such as the long-acting version – produced in Poland can be refunded but, according to Blaszczyk, the more needed recombinant insulin is not on the list of medicines from which Polish users can obtain a refund. Insulin is reportedly used by about 200,000 Poles.